| abstract |
A compound selected from the formula I: and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein: R1 and R2 are independently selected from hydrogen, halogen, CN, C1-C3 alkyl and C1-C3 alkoxy; R3 is hydrogen, halogen or C1-C3 alkyl; R4 is C3-C5 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl, phenyl, a 5-6 membered heteroaryl or NRgRh, wherein the cycloalkyl, alkyl, alkenyl, alkynyl, phenyl and heteroaryl are optionally substituted with ORc, halogen, phenyl, C3-C4 cycloalkyl, or C1-C4 alkyl optionally substituted with halogen; R5 is: hydrogen, halogen, CN, NRcRd, ORe, SRf, phenyl optionally substituted with one to three Ra groups, a 5-6 membered heteroaryl optionally substituted with C1-C4 alkyl, a saturated or partially unsaturated C3-C6 cycloalkyl optionally substituted with halogen or C1-C4 alkyl, a saturated or partially unsaturated 4-6 membered heterocyclyl optionally substituted with C1-C4 alkyl, C2-C6 alkynyl optionally substituted with halogen, ORc or NRcRd, C2-C6 alkenyl optionally substituted with halogen , ORc or NRcRd, or C1-C6 alkyl optionally substituted with one to three Rb groups; each Ra is independently selected from halogen, CF3, C1-C4 alkyl or -O (C1-C4 alkyl), in which the alkyl or alkoxy is optionally substituted with OH, NRcRd or a 5-6 membered heterocyclyl optionally substituted with alkyl C1-C3; each Rb is independently selected from halogen, OH, OCH3, oxo, -NRcRd or C3-C6 cycloalkyl; each Rc and Rd are independently selected from hydrogen, phenyl and C1-C4 alkyl optionally substituted with oxo; Re is selected from a 4-6 membered heterocyclyl and C1-C6 alkyl optionally substituted with halogen, OH, OCH3, C3-C6 cycloalkyl or a 4-6 membered heterocyclyl; Rf is C1-C6 alkyl; and Rg and Rh are independently selected from hydrogen and C1-C5 alkyl optionally substituted with halogen, or Rg and Rh together with the nitrogen to which they are attached form a 4- to 6-membered heterocyclic ring. |